Medicina-buenos Aires最新文献_第3页

[Malaria and paludism: a necessary clarification]. [疟疾和疟疾：必要的澄清]。

IF 0.6 4区医学

Medicina-buenos Aires Pub Date : 2025-01-01

Mario O Melcon, Celeste Garcías

引用次数: 0

[Mechanisms of tricuspid insufficiency in the follow-up of patients post orthotopic heart transplantation]. [原位心脏移植术后随访中三尖瓣功能不全的机制]。

IF 0.6 4区医学

Medicina-buenos Aires Pub Date : 2025-01-01

Pilar Domenech, Estefanía Mestrallet, Ricardo Posatini, César Belziti, Rodolfo Pizarro

{"title":"[Mechanisms of tricuspid insufficiency in the follow-up of patients post orthotopic heart transplantation].","authors":"Pilar Domenech, Estefanía Mestrallet, Ricardo Posatini, César Belziti, Rodolfo Pizarro","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Tricuspid regurgitation (TR) is the most frequent valvulopathy after cardiac transplantation, with an incidence ranging from 19% to 84%. Severity increases with follow-up. The objectives were to describe the mechanisms involved in the development of post-transplantation TR.Materials and methods: Single-center, retrospective cohort study including patients who received orthotopic heart transplantation between 2012 and 2022. Echocardiograms were performed at 6, 12 and 18 months' post-transplantation. The mechanisms of tricuspid regurgitation described were atrial dilatation or bi-atrial technique, multiple endomyocardial biopsies, right ventricular dilatation and dysfunction, previous pulmonary hypertension and mismatch of the recipient cavity with the transplanted organ.Results: A total of 234 patients were included. The incidence of significant tricuspid regurgitation from 6 months post-transplantation was 12.8%. Right ventricular dilatation and dysfunction was the most prevalent mechanism in 67%, mismatch 17%, organic valve lesion and previous pulmonary hypertension 7% and atrial dilatation 3%. The 40% of patients who had right ventricular dysfunction also presented left ventricular dysfunction.Discussion: The incidence of tricuspid regurgitation in heart transplant patients was 12.8% during the follow-up. The main mechanism observed was the right ventricular dilatation and dysfunction.","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"85 2","pages":"331-336"},"PeriodicalIF":0.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Acromegaly as a differential diagnosis of hyperphosphatemia]. 肢端肥大症作为高磷血症的鉴别诊断。

IF 0.6 4区医学

Medicina-buenos Aires Pub Date : 2025-01-01

Mariela Varsavsky, Mariela Glerean, Mirena Buttazzoni

{"title":"[Acromegaly as a differential diagnosis of hyperphosphatemia].","authors":"Mariela Varsavsky, Mariela Glerean, Mirena Buttazzoni","doi":"","DOIUrl":"","url":null,"abstract":"Acromegaly is characterized by hypersecretion of growth hormone (GH) caused by a pituitary adenoma in 99% of cases. Increased serum phosphate is a rare finding in this pathology. This hyperphosphatemia results from increased phosphate reabsorption in the proximal renal tubule via sodium-phosphate cotransporter type IIa: an effect mediated by insulin-like factor 1 (IGF-1) consequent to excess GH. We present the clinical case of a 66-year-old woman with persistent hyperphosphatemia 4.8 ng/dl (VN: 2.5-4.5) with elevated tubular phosphorus reabsorption (TPR) 95% (VN: 85-94) with subtle features of acromegaly. Acromegaly was diagnosed by IGF1 measurements and oral glucose tolerance test with GH measurement (OGTT/GH). In search of the source of GH hypersecretion, a pituitary MRI was requested, and the pituitary microadenoma was evident only in the third year of follow-up. Achieving remission of the disease (IGF-1 in normal range) after transsphenoidal endoscopic surgery and observing normalization of previous hyperphosphatemia. No evidence of recurrence was found in the 18 years of follow-up. In cases of hyperphosphatemia to review the signs and symptoms of acromegaly to diagnose and treat in early stages, when the probability of remission is high.","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"85 2","pages":"434-438"},"PeriodicalIF":0.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fabry disease in Argentina: clinical, biochemical and molecular correlation in all reported GLA variants. 阿根廷法布里病：所有报告的GLA变异的临床、生化和分子相关性

IF 0.6 4区医学

Medicina-buenos Aires Pub Date : 2025-01-01

Juan Politei, Romina Ceci, Domingo Procopio, Lucas Silvestroff, Rita Valdez, Paula A Rozenfeld

{"title":"Fabry disease in Argentina: clinical, biochemical and molecular correlation in all reported GLA variants.","authors":"Juan Politei, Romina Ceci, Domingo Procopio, Lucas Silvestroff, Rita Valdez, Paula A Rozenfeld","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Fabry disease is an X-linked trait due to pathogenic variants in the GLA gene, causing deficient GLA enzyme activity, and producing a chronic accumulation of globotriaosylceramide and its derivative globotriaosylsphingosine (LysoGb3) in tissues and fluids. Conflicting or discordant results of interpretation of multiple variants in GLA were reported in literature. The aim of this article is to report the spectrum of GLA variants in Argentine population, as well as the revised interpretation of variants classification. Moreover, we intend to find a possible correlation between biochemical parameters, clinical manifestations and genetic variants of adult male Fabry patients that could be of help for interpretation of variants.Materials and methods: Blood samples from patients with clinical suspicion of Fabry disease were evaluated for specific laboratory tests: alfa-galactosidase A enzyme activity, LysoGb3 and GLA genetic test.Results: There are 44 males with pathogenic GLA variants which showed deficient enzyme activity. Among them, thirty-two presented the classic phenotype (72%) and twelve the late onset clinical features (28%). Mean percentage of enzyme activity was 0.9% for classical patients and 3.2% for later onset ones. LysoGb3 values were increased in all males, with classic patients showing considerable higher values than that of late onset.Discussion: Our results showed that the combined analysis of the clinical picture, leukocyte enzyme activity, globotriaosylsphingosine concentration and a detailed exhaustive study of the genetic variant lead to a definite diagnosis in those cases previously interpreted as of unknown significance, together with a revised interpretation of the phenotype.","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"85 2","pages":"322-330"},"PeriodicalIF":0.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Dose banding. Observational study on cost optimization in chemotherapy]. (剂量条带。化疗成本优化的观察性研究[j]。

IF 0.6 4区医学

Medicina-buenos Aires Pub Date : 2025-01-01

José M Sanguinetti, Federico N Cisneros, Gustavo H Marin

{"title":"[Dose banding. Observational study on cost optimization in chemotherapy].","authors":"José M Sanguinetti, Federico N Cisneros, Gustavo H Marin","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: The cost of cancer treatments is a concern of the health system. The search for strategies that optimize the costs of these treatments is essential to ensure access to them. Dose banding is a methodology that has been successfully implemented in several countries, demonstrating effectiveness and efficiency. It is based on establishing dose bands rounding cytostatics ±5% and monoclonal antibodies ±10%, optimizing commercial presentations and avoiding waste. In our country there are no experiences with this system. The objective was to evaluate the savings in drug costs using dose banding.Material and methods: Observational study of the costs of oncology drugs in a sample of patients affiliated with the Institute of Social Work of the Armed Forces (IOSFA) diagnosed with breast, colon and prostate cancer who received treatment during June 2022. The cost of each dose was determined and was simulated according to the dose banding system.Results: Twenty-eight patients who received 29 doses were analysed.Diagnoses: colon cancer (n:7; 25.0%), breast cancer (n:18; 64.3%) and prostate cancer (n:3; 10.7%). Mean age 61.7 years (range 34-85 years); 22 patients were female. Drugs tested: bevacizumab, cabazitaxel, cetuximab, docetaxel, trastuzumab, and trastuzumab+emtasine. The total cost was $14 101 596.39 (U$S 112 605.58 -sale value of the U.S. dollar in the Banco Nación Argentina, June 30, 2022), the simulation of the application of dose banding showed a cost of $11 185 371.49 (U$S 89 318.63). The potential savings are 20.7%.Discussion: Dose standardization may represent a strategy that generates a significant decrease in cancer treatment costs.","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"85 1","pages":"96-100"},"PeriodicalIF":0.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Breastfeeding in people with HIV, from taboo to reality]. 艾滋病毒感染者的母乳喂养，从禁忌到现实。

IF 0.6 4区医学

Medicina-buenos Aires Pub Date : 2025-01-01

Leda Guzzi, Silvana Lauro, Gloria Amborosioni, Pilar Cancela, Mónica Castells, Claudio Comparato, Rocío López, Natalia Laufer, Isabel Casetti

引用次数: 0

[Update on the treatment of hereditary angioedema in Argentina]. 【阿根廷遗传性血管性水肿治疗的最新进展】。

IF 0.6 4区医学

Medicina-buenos Aires Pub Date : 2025-01-01

Blas Larrauri, Alejandro Malbrán, Eloisa Malbrán

引用次数: 0

[Coinfection with two dengue serotypes during the 2024 outbreak]. [在 2024 年登革热爆发期间同时感染两种登革热血清型]。